ACCURATE EASY TO USE AND NON INVASIVE DEVICE FOR EARLY DETECTION AND MONITORING...
ACCURATE EASY TO USE AND NON INVASIVE DEVICE FOR EARLY DETECTION AND MONITORING OF HEART FAILURE IN REAL TIME
Heart Failure (HF) affects 15 million of Europeans and €6.41 billion are annually spent on its management and treatment by the healthcare system, CORALERT aims to favour the HF prevention and decrease its costs through its innovat...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
V-LAP
A revolutionary direct daily heart monitoring platform for...
3M€
Cerrado
RETENTION
heaRt failurE paTient managEment and iNTerventIOns usiNg con...
6M€
Cerrado
V-LAP
Saving millions of lives by enabling an effective treatment...
71K€
Cerrado
Cardiacom IMPLANT
Intelligent human diagnostic and therapy platform
71K€
Cerrado
EGM
A disruptive life saving solution for early detection of lun...
71K€
Cerrado
Información proyecto NIRT MONITOR
Duración del proyecto: 4 meses
Fecha Inicio: 2019-07-09
Fecha Fin: 2019-11-30
Líder del proyecto
CORALERT LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Heart Failure (HF) affects 15 million of Europeans and €6.41 billion are annually spent on its management and treatment by the healthcare system, CORALERT aims to favour the HF prevention and decrease its costs through its innovative NIRT MONITOR medical device. Gold standard procedures for diagnosing HF using catheterization are risky and complexes. As validated by clinical assay, NIRT MONITOR offers an alternative, safe and easy to use method to early diagnosis HF in real time by non-invasive measuring of LVEDP (Left Ventricular End Diastolic Pressure) providing physicians and in- and out-patient settings an early diagnosis of HF and its complications. NIRT MONITOR will improve the quality of life of patients while reducing hospitalizations by 30% and re-admissions by 80%. Cardiology, ICU, ER and Internal Medicine Units from hospitals (€5.1 billion of European market), GP offices and homecare settings will be the target users. NIRT MONITOR business model will be based on devices sales/leasing for early adopters and later from indirect sales/leasing through medical technology distributors. Revenues will be also generated by direct and indirect sales of disposables and by Cloud App payment fees. NIRT MONITOR will be an inexpensive solution (€10,000/device) in comparison with one catheter lab procedure (first two uses will save the 100% of the costs of one use of the standard method). NIRT MONITOR´s safety, easy to use, cost-efficient and accuracy will ensure its penetration into targeted European countries (Spain, France and Germany) and expansion over other European countries and US. We estimate a profit of ≈€38.5M after four years of commercialization with a ROI of 11.8 and a market share of 4.5%. We have filled US and PCT patent applications. To ensure the sucessful release of NIRT MONITOR into the market, a feasibility study will be performed during SME Phase 1 to evaluate any technical, commercial and financial issues related to the project.